Zymeworks (NASDAQ:ZYME) said it has achieved a $14M cash research milestone through its collaboration with GSK (GSK). Under ...

Clinical validation of the Azymetric platform is demonstrated by the accelerated approval of Ziihera® (zanidatamab-hrii), a treatment for advanced HER2-positive biliary tract cancer in adults who have ...

GSK (GSK) came out with quarterly earnings of ... Another stock from the same industry, Zymeworks Inc. (ZYME), has yet to report results for the quarter ended September 2024.

The California biotech had reached an agreement with Iconic and Zymeworks giving the option on the drug in May last year. Probably best known for the cancer drug Cabometyx (cabozantinib), which is ...

Jazz Pharmaceuticals and Zymeworks, Inc. have announced that Jazz and Zymeworks BC, Inc. (a Zymeworks subsidiary) have entered into a licensing agreement, under which Jazz is to acquire the ...

Zymeworks (ZYME) announced achievement of a $14M cash research milestone from GSK (GSK) associated with a clinical milestone. “In April 2016, ...